A Bowel Management Program (Retrograde Rectal Enema) for the Treatment of Low Anterior Resection Syndrome in Rectal Cancer Patients
Launched by OHIO STATE UNIVERSITY COMPREHENSIVE CANCER CENTER · May 16, 2024
Trial Information
Current as of February 08, 2025
Not yet recruiting
Keywords
ClinConnect Summary
PRIMARY OBJECTIVE:
I. To compare two approved pathways for treatment of low anterior resection syndrome (LARS) - a retrograde enema program versus a medical management pathway.
SECONDARY OBJECTIVE:
I. The determination of feasibility to complete this treatment pathway.
OUTLINE: Patients are randomized to 1 of 2 groups.
GROUP I: Patients undergo a bowel management program comprising a medical management pathway (fiber, loperamide hydrochloride, pelvic floor physical therapy) in combination with RRE treatment for 1 year. Patients use the RRE system to self administer an individualized en...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years old
- • LARS diagnosis
- • Patients with history of rectal cancer
- Exclusion Criteria:
- • Patients presenting with significant stricture that need a definitive surgical management strategy; patients with minor or clinically negligible strictures can still be candidates. Patients who are able to pass the catheter and the balloon per rectum may be candidates after a digital rectal exam at their initial visit
- • Patients with any chemo or radiation therapy in the last 6 months
- • Patients who currently have colorectal cancer
- • Patients with recurrent colorectal cancer
- • Patients who have undergone a colorectal surgical procedure within the last three months
- • Patients \< 18 years old
- • Active sacral nerve simulator
- • Altered mental status or mental disability that would alter ability to self-administer enema
- • Any reason the research team believes the subject is not an appropriate candidate for this study (i.e., transportation issues, history of no-show appointments, lack of reliable communications, vulnerable population(s), etc.)
Trial Officials
Alessandra C Gasior, DO
Principal Investigator
Ohio State University Comprehensive Cancer Center
About Ohio State University Comprehensive Cancer Center
The Ohio State University Comprehensive Cancer Center (OSUCCC) is a leading institution dedicated to advancing cancer research, treatment, and education. As a National Cancer Institute-designated comprehensive cancer center, OSUCCC integrates cutting-edge research with clinical practice to develop innovative therapies and improve patient outcomes. With a collaborative approach that unites scientists and clinicians, OSUCCC focuses on personalized medicine, cancer prevention, and community outreach, striving to enhance the understanding of cancer biology and provide hope to patients through groundbreaking clinical trials and comprehensive care programs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Columbus, Ohio, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0